579 related articles for article (PubMed ID: 33406763)
1. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
[TBL] [Abstract][Full Text] [Related]
2. Adaptive immunity: an emerging player in the progression of NAFLD.
Sutti S; Albano E
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):81-92. PubMed ID: 31605031
[TBL] [Abstract][Full Text] [Related]
3. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
4. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD).
Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E
Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340
[TBL] [Abstract][Full Text] [Related]
5. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
6. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M
Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
Zhou L; Shen H; Li X; Wang H
Front Immunol; 2022; 13():951406. PubMed ID: 35958574
[TBL] [Abstract][Full Text] [Related]
8. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Pierantonelli I; Svegliati-Baroni G
Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
[TBL] [Abstract][Full Text] [Related]
11. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria in non-alcoholic fatty liver disease.
Simões ICM; Fontes A; Pinton P; Zischka H; Wieckowski MR
Int J Biochem Cell Biol; 2018 Feb; 95():93-99. PubMed ID: 29288054
[TBL] [Abstract][Full Text] [Related]
14. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.
Kitade H; Chen G; Ni Y; Ota T
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420094
[TBL] [Abstract][Full Text] [Related]
16. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
18. [Nonalcoholic fatty liver disease].
Lemoine M; Serfaty L
Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
[TBL] [Abstract][Full Text] [Related]
19. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?
Tariq Z; Green CJ; Hodson L
Liver Int; 2014 Aug; 34(7):e180-90. PubMed ID: 24621397
[TBL] [Abstract][Full Text] [Related]
20. Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis.
Hughey CC; Puchalska P; Crawford PA
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Nov; 1867(11):159209. PubMed ID: 35934297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]